Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
Related Articles
KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer
PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.
Long-Term Data Suggest Potential Functional Cure With MCL2/MCL3 Regimen in Younger Patients With Mantle Cell Lymphoma
Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.
High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
Pooled Trial Data Highlight Potential of a Novel Biparatopic ADC in Heavily Pretreated HER2+ Breast Cancer
JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.
ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC
In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.
Second-Generation BTK Inhibitors Set the Stage for Future Advances in CLL Management
Cyrus M. Khan, MD, discusses the role of second-generation BTK inhibitors and their implications for clinical practice in the CLL treatment paradigm.
Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC
Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.